|
DK3211085T3
(da)
|
2003-09-30 |
2021-06-21 |
Univ Pennsylvania |
Klader af adeno-associeret virus (aav), sekvenser, vektorer indeholdende disse og anvendelser deraf
|
|
US9217155B2
(en)
|
2008-05-28 |
2015-12-22 |
University Of Massachusetts |
Isolation of novel AAV'S and uses thereof
|
|
WO2010138263A2
(en)
|
2009-05-28 |
2010-12-02 |
University Of Massachusetts |
Novel aav 's and uses thereof
|
|
DK2826860T3
(en)
|
2010-04-23 |
2018-12-03 |
Univ Massachusetts |
CNS targeting AAV vectors and methods for their use
|
|
EP2561075B1
(en)
|
2010-04-23 |
2018-06-27 |
University of Massachusetts |
Aav-based treatment of cholesterol-related disorders
|
|
JP6042825B2
(ja)
|
2011-02-10 |
2016-12-14 |
ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル |
改変された形質導入プロファイルを有するウイルスベクターならびにその製造および使用の方法
|
|
ES2724800T3
(es)
|
2011-02-17 |
2019-09-16 |
Univ Pennsylvania |
Composiciones y métodos para alterar la especificidad de tejido y mejorar la transferencia génica mediada por AAV9
|
|
EP3318634A1
(en)
|
2011-04-21 |
2018-05-09 |
University of Massachusetts |
Raav-based compositions and methods for treating diseases involving dominant-negative or gain of function mutations
|
|
WO2013170078A1
(en)
*
|
2012-05-09 |
2013-11-14 |
Oregon Health & Science University |
Adeno associated virus plasmids and vectors
|
|
EP2749569A1
(en)
|
2012-12-28 |
2014-07-02 |
Annibale Alessandro Puca |
Variant of BPIFB4 protein
|
|
US20140219964A1
(en)
|
2013-02-07 |
2014-08-07 |
Children's Medical Center Corporation |
Methods for inducing cardiomyocyte proliferation
|
|
EP2970946A4
(en)
*
|
2013-03-13 |
2016-09-07 |
Philadelphia Children Hospital |
ADENOASSOZED VIRUS VECTORS AND METHOD FOR USE THEREOF
|
|
SG10201707319UA
(en)
|
2013-03-15 |
2017-10-30 |
Univ Pennsylvania |
Compositions and methods for treating mpsi
|
|
CN105163764B
(zh)
*
|
2013-03-15 |
2019-11-12 |
北卡罗来纳-查佩尔山大学 |
双重聚糖结合aav载体的方法和组合物
|
|
EP3628334B1
(en)
|
2014-03-21 |
2023-06-28 |
Genzyme Corporation |
Gene therapy for retinitis pigmentosa
|
|
WO2015164757A1
(en)
*
|
2014-04-25 |
2015-10-29 |
Oregon Health & Science University |
Methods of viral neutralizing antibody epitope mapping
|
|
WO2015187825A2
(en)
|
2014-06-03 |
2015-12-10 |
University Of Massachusetts |
Compositions and methods for modulating dysferlin expression
|
|
WO2015191508A1
(en)
|
2014-06-09 |
2015-12-17 |
Voyager Therapeutics, Inc. |
Chimeric capsids
|
|
EP4012035B1
(en)
|
2014-09-16 |
2024-11-06 |
Genzyme Corporation |
Adeno-associated viral vectors for treating myocilin (myoc) glaucoma
|
|
WO2016044478A1
(en)
|
2014-09-16 |
2016-03-24 |
Genzyme Corporation |
Adeno-associated viral vectors for treating myocilin (myoc) glaucoma
|
|
EP3795580A1
(en)
|
2014-10-03 |
2021-03-24 |
University of Massachusetts |
High efficiency library-identified aav vectors
|
|
WO2016054554A1
(en)
|
2014-10-03 |
2016-04-07 |
University Of Massachusetts |
Heterologous targeting peptide grafted aavs
|
|
WO2016065001A1
(en)
|
2014-10-21 |
2016-04-28 |
University Of Massachusetts |
Recombinant aav variants and uses thereof
|
|
CN112553229A
(zh)
|
2014-11-05 |
2021-03-26 |
沃雅戈治疗公司 |
用于治疗帕金森病的aadc多核苷酸
|
|
RU2020108189A
(ru)
|
2014-11-14 |
2020-03-11 |
Вояджер Терапьютикс, Инк. |
Композиции и способы лечения бокового амиотрофического склероза (als)
|
|
MX2017006217A
(es)
|
2014-11-14 |
2018-05-02 |
Voyager Therapeutics Inc |
Polinucleotidos moduladores.
|
|
EP3230441A4
(en)
|
2014-12-12 |
2018-10-03 |
Voyager Therapeutics, Inc. |
Compositions and methods for the production of scaav
|
|
IL296391B2
(en)
|
2015-01-20 |
2024-06-01 |
Genzyme Corp |
Analytical ultracentrifugation for characterization of recombinant viral particles
|
|
SG11201706444TA
(en)
|
2015-02-10 |
2017-09-28 |
Genzyme Corp |
VARIANT RNAi
|
|
NZ772772A
(en)
|
2015-02-10 |
2024-12-20 |
Genzyme Corp |
Enhanced delivery of viral particles to the striatum and cortex
|
|
US10584321B2
(en)
|
2015-02-13 |
2020-03-10 |
University Of Massachusetts |
Compositions and methods for transient delivery of nucleases
|
|
TWI707951B
(zh)
|
2015-04-08 |
2020-10-21 |
美商健臻公司 |
過大腺相關載體之製造
|
|
CA3021949C
(en)
|
2015-04-24 |
2023-10-17 |
University Of Massachusetts |
Modified aav constructs and uses thereof
|
|
WO2016186772A2
(en)
|
2015-05-16 |
2016-11-24 |
Genzyme Corporation |
Gene editing of deep intronic mutations
|
|
US20180214576A1
(en)
*
|
2015-07-28 |
2018-08-02 |
University Of Massachusetts |
Transgenic expression of dnasei in vivo delivered by an adeno-associated virus vector
|
|
US11426469B2
(en)
|
2015-10-22 |
2022-08-30 |
University Of Massachusetts |
Prostate-targeting adeno-associated virus serotype vectors
|
|
WO2017070525A1
(en)
|
2015-10-22 |
2017-04-27 |
University Of Massachusetts |
Methods and compositions for treating metabolic imbalance in neurodegenerative disease
|
|
AU2016362477A1
(en)
|
2015-12-02 |
2018-06-14 |
Voyager Therapeutics, Inc. |
Assays for the detection of AAV neutralizing antibodies
|
|
US11015173B2
(en)
|
2015-12-11 |
2021-05-25 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for AAV1
|
|
EP3387118B1
(en)
|
2015-12-11 |
2022-04-06 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for aavrh10
|
|
US11098286B2
(en)
|
2015-12-11 |
2021-08-24 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for AAV9
|
|
WO2017100676A1
(en)
|
2015-12-11 |
2017-06-15 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for aav8
|
|
CA3008268A1
(en)
|
2015-12-15 |
2017-06-22 |
Genzyme Corporation |
Adeno-associated viral vectors for treating mucolipidosis type ii
|
|
EP3411059A4
(en)
|
2016-02-02 |
2019-10-16 |
University Of Massachusetts |
METHOD FOR INCREASING THE EFFECTIVENESS OF THE SYSTEMIC DELIVERY OF AVV GENES TO THE CENTRAL NERVOUS SYSTEM
|
|
WO2017136500A1
(en)
|
2016-02-03 |
2017-08-10 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treating mucopolysaccharidosis type i
|
|
EP3413928B1
(en)
|
2016-02-12 |
2022-04-20 |
University of Massachusetts |
Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization
|
|
US11207426B2
(en)
|
2016-04-05 |
2021-12-28 |
University Of Massachusetts |
Compositions and methods for selective inhibition of grainyhead-like protein expression
|
|
WO2017181113A1
(en)
|
2016-04-15 |
2017-10-19 |
The Trustees Of The University Of Pennsyvania |
Gene therapy for treating mucopolysaccharidosis type ii
|
|
WO2017181105A1
(en)
|
2016-04-15 |
2017-10-19 |
University Of Massachusetts |
Methods and compositions for treating metabolic imbalance
|
|
EP3448874A4
(en)
|
2016-04-29 |
2020-04-22 |
Voyager Therapeutics, Inc. |
COMPOSITIONS FOR TREATING A DISEASE
|
|
US11299751B2
(en)
|
2016-04-29 |
2022-04-12 |
Voyager Therapeutics, Inc. |
Compositions for the treatment of disease
|
|
CN116333057A
(zh)
|
2016-05-13 |
2023-06-27 |
4D分子治疗有限公司 |
腺相关病毒变体衣壳和其使用方法
|
|
BR112018073472A2
(pt)
|
2016-05-18 |
2019-08-27 |
Voyager Therapeutics, Inc. |
composições e métodos de tratamento da doença de huntington
|
|
AU2017267665C1
(en)
|
2016-05-18 |
2023-10-05 |
Voyager Therapeutics, Inc. |
Modulatory polynucleotides
|
|
WO2017218852A1
(en)
|
2016-06-15 |
2017-12-21 |
University Of Massachusetts |
Recombinant adeno-associated viruses for delivering gene editing molecules to embryonic cells
|
|
CN106093369B
(zh)
*
|
2016-06-29 |
2017-10-20 |
福建农林大学 |
Bt水稻对非靶标害虫褐飞虱的安全性评价方法
|
|
US11698377B2
(en)
|
2016-08-15 |
2023-07-11 |
Genzyme Corporation |
Methods for detecting AAV
|
|
WO2018044933A1
(en)
|
2016-08-30 |
2018-03-08 |
The Regents Of The University Of California |
Methods for biomedical targeting and delivery and devices and systems for practicing the same
|
|
US10457940B2
(en)
|
2016-09-22 |
2019-10-29 |
University Of Massachusetts |
AAV treatment of Huntington's disease
|
|
US11578340B2
(en)
|
2016-10-13 |
2023-02-14 |
University Of Massachusetts |
AAV capsid designs
|
|
EP3558393A4
(en)
*
|
2016-12-22 |
2020-11-11 |
Oregon Health & Science University |
ADENO-ASSOCIATED VIRAL VECTORS
|
|
CA3061652A1
(en)
|
2017-05-05 |
2018-11-08 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating amyotrophic lateral sclerosis (als)
|
|
CN111108198A
(zh)
|
2017-05-05 |
2020-05-05 |
沃雅戈治疗公司 |
治疗亨廷顿病的组合物和方法
|
|
JOP20190269A1
(ar)
|
2017-06-15 |
2019-11-20 |
Voyager Therapeutics Inc |
بولي نوكليوتيدات aadc لعلاج مرض باركنسون
|
|
AU2018298133A1
(en)
|
2017-07-06 |
2020-01-23 |
The Trustees Of The University Of Pennsylvania |
AAV9-mediated gene therapy for treating mucopolysaccharidosis type I
|
|
CN111132626B
(zh)
|
2017-07-17 |
2024-01-30 |
沃雅戈治疗公司 |
轨迹阵列引导系统
|
|
BR112020005436B1
(pt)
|
2017-09-20 |
2022-08-02 |
4D Molecular Therapeutics Inc |
Proteína do capsídeo de variante do vírus adenoassociado, virion do aav recombinante (raav) infeccioso, composições, composições farmacêuticas e usos de virion de raav ou de composições farmacêuticas
|
|
WO2019060662A1
(en)
|
2017-09-22 |
2019-03-28 |
The Trustees Of The University Of Pennsylvania |
GENE THERAPY FOR THE TREATMENT OF MUCOPOLYSACCHARIDOSE TYPE II
|
|
MY205041A
(en)
|
2017-09-22 |
2024-09-29 |
Genzyme Corp |
Variant rnai
|
|
AU2018338728B2
(en)
|
2017-09-29 |
2025-01-02 |
Centre National De La Recherche Scientifique (Cnrs) |
Rescue of central and peripheral neurological phenotype of Friedreich's Ataxia by intravenous delivery
|
|
CN111479924B
(zh)
|
2017-10-16 |
2024-06-14 |
沃雅戈治疗公司 |
肌萎缩性侧索硬化症(als)的治疗
|
|
US20200237799A1
(en)
|
2017-10-16 |
2020-07-30 |
Voyager Therapeutics, Inc. |
Treatment of amyotrophic lateral sclerosis (als)
|
|
FI3717636T3
(fi)
|
2017-11-27 |
2023-06-01 |
4D Molecular Therapeutics Inc |
Adenoassosioidun viruksen kapsidivariantteja ja käyttö angiogeneesin estämisessä
|
|
US20190256867A1
(en)
|
2018-02-01 |
2019-08-22 |
Homology Medicines, Inc. |
Adeno-associated virus compositions for restoring pah gene function and methods of use thereof
|
|
PE20210341A1
(es)
*
|
2018-02-01 |
2021-02-23 |
Homology Medicines Inc |
Composiciones de virus adeno-asociadas para la transferencia de genes pah y metodos de uso de los mismos
|
|
US10610606B2
(en)
|
2018-02-01 |
2020-04-07 |
Homology Medicines, Inc. |
Adeno-associated virus compositions for PAH gene transfer and methods of use thereof
|
|
CN112041437A
(zh)
|
2018-02-19 |
2020-12-04 |
同源药物公司 |
用于恢复f8基因功能的腺相关病毒组合物和其使用方法
|
|
CA3093347A1
(en)
|
2018-04-05 |
2019-10-10 |
Genethon |
Hybrid recombinant adeno-associated virus serotype between aav9 and aavrh74 with reduced liver tropism
|
|
US12460226B2
(en)
|
2018-04-16 |
2025-11-04 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treating duchenne muscular dystrophy
|
|
JP2021523702A
(ja)
*
|
2018-05-04 |
2021-09-09 |
オレゴン ヘルス アンド サイエンス ユニバーシティ |
ヒト抗ａａｖ２カプシドポリクローナル抗体エピトープ
|
|
AU2019268330A1
(en)
|
2018-05-15 |
2020-11-26 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of Parkinson's disease
|
|
US12163129B2
(en)
|
2018-06-08 |
2024-12-10 |
University Of Massachusetts |
Antisense oligonucleotides to restore dysferlin protein expression in dysferlinopathy patient cells
|
|
US12060567B2
(en)
|
2018-06-13 |
2024-08-13 |
Voyager Therapeutics, Inc. |
Engineered untranslated regions (UTR) for AAV production
|
|
MX2021000810A
(es)
|
2018-07-24 |
2021-04-28 |
Voyager Therapeutics Inc |
Sistemas y metodos para producir formulaciones de terapia genetica.
|
|
MX2021001395A
(es)
|
2018-08-03 |
2021-08-11 |
Genzyme Corp |
Arni variante contra alfa-sinucleína.
|
|
EP3856762A1
(en)
|
2018-09-28 |
2021-08-04 |
Voyager Therapeutics, Inc. |
Frataxin expression constructs having engineered promoters and methods of use thereof
|
|
TW202035689A
(zh)
|
2018-10-04 |
2020-10-01 |
美商航海家醫療公司 |
測量病毒載體粒子的效價及強度之方法
|
|
WO2020072844A1
(en)
|
2018-10-05 |
2020-04-09 |
Voyager Therapeutics, Inc. |
Engineered nucleic acid constructs encoding aav production proteins
|
|
EP4461814A3
(en)
|
2018-10-12 |
2025-02-26 |
Genzyme Corporation |
Generation of improved human pah for treatment of severe pku by liver-directed gene replacement therapy
|
|
UY38407A
(es)
|
2018-10-15 |
2020-05-29 |
Novartis Ag |
Anticuerpos estabilizadores de trem2
|
|
CN113166781A
(zh)
|
2018-10-15 |
2021-07-23 |
沃雅戈治疗公司 |
在杆状病毒/Sf9系统中大规模生产rAAV的表达载体
|
|
KR20210130158A
(ko)
|
2019-01-31 |
2021-10-29 |
오레곤 헬스 앤드 사이언스 유니버시티 |
Aav 캡시드의 전사 의존적 유도 진화를 사용하는 방법
|
|
BR112021016501A2
(pt)
|
2019-02-25 |
2021-10-26 |
Novartis Ag |
Composições e métodos para tratar distrofia cristalina de bietti
|
|
US20220154211A1
(en)
|
2019-02-25 |
2022-05-19 |
Novartis Ag |
Compositions and methods to treat bietti crystalline dystrophy
|
|
WO2020176747A1
(en)
|
2019-02-28 |
2020-09-03 |
Regeneron Pharmaceuticals, Inc. |
Adeno-associated virus vectors for the delivery of therapeutics
|
|
US12398378B2
(en)
|
2019-04-12 |
2025-08-26 |
University Of Massachusetts |
AAV-mediated gene therapy for maple syrup urine disease (MSUD)
|
|
JP7707081B2
(ja)
*
|
2019-05-17 |
2025-07-14 |
リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル |
網膜細胞を標的とした最適化された遺伝子治療
|
|
US10557149B1
(en)
|
2019-07-15 |
2020-02-11 |
Vigene Biosciences, Inc. |
Recombinantly-modified adeno-associated virus helper vectors and their use to improve the packaging efficiency of recombinantly-modified adeno-associated virus
|
|
US10653731B1
(en)
|
2019-07-15 |
2020-05-19 |
Vigene Biosciences Inc. |
Recombinantly-modified adeno-associated virus (rAAV) having improved packaging efficiency
|
|
US10801042B1
(en)
|
2019-07-15 |
2020-10-13 |
Vigene Biosciences, Inc. |
Use of ion concentrations to increase the packaging efficiency of recombinant adeno-associated virus
|
|
IL292297A
(en)
*
|
2019-10-17 |
2022-06-01 |
Stridebio Inc |
Adeno-associated viral vectors for treatment of niemann-pick disease type c
|
|
CA3159620A1
(en)
*
|
2019-11-01 |
2021-05-06 |
Sangamo Therapeutics, Inc. |
Compositions and methods for genome engineering
|
|
TW202140791A
(zh)
|
2020-01-13 |
2021-11-01 |
美商霍蒙拉奇醫藥公司 |
治療苯酮尿症之方法
|
|
TW202208632A
(zh)
|
2020-05-27 |
2022-03-01 |
美商同源醫藥公司 |
用於恢復ｐａｈ基因功能的腺相關病毒組成物及其使用方法
|
|
WO2022051468A1
(en)
|
2020-09-04 |
2022-03-10 |
Milwaukee Electric Tool Corporation |
Chainsaw
|
|
JP2023544165A
(ja)
|
2020-10-01 |
2023-10-20 |
ジェンザイム・コーポレーション |
肝臓に向けられた遺伝子補充療法によってｐｋｕを処置するためのヒトｐａｈ発現カセット
|
|
EP4284335A1
(en)
|
2021-02-01 |
2023-12-06 |
RegenxBio Inc. |
Gene therapy for neuronal ceroid lipofuscinoses
|
|
AU2022318664A1
(en)
|
2021-07-30 |
2024-02-29 |
Tune Therapeutics, Inc. |
Compositions and methods for modulating expression of methyl-cpg binding protein 2 (mecp2)
|
|
WO2023010133A2
(en)
|
2021-07-30 |
2023-02-02 |
Tune Therapeutics, Inc. |
Compositions and methods for modulating expression of frataxin (fxn)
|
|
KR20240137067A
(ko)
*
|
2022-01-25 |
2024-09-19 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
개선된 심장 형질도입 및 간의 탈표적화를 위한 aav 캡시드
|
|
CA3255627A1
(en)
|
2022-05-06 |
2023-11-09 |
Novartis Ag |
NEW VP2 FUSION POLYPEPTIDES OF RECOMBINANT AAV
|
|
CA3261865A1
(en)
|
2022-07-12 |
2024-01-18 |
Tune Therapeutics, Inc. |
TARGETED TRANSCRIPTIONAL ACTIVATION COMPOSITIONS, SYSTEMS AND METHODS
|
|
WO2024163683A2
(en)
|
2023-02-01 |
2024-08-08 |
Tune Therapeutics, Inc. |
Systems, compositions, and methods for modulating expression of methyl-cpg binding protein 2 (mecp2) and x-inactive specific transcript (xist)
|
|
WO2024163678A2
(en)
|
2023-02-01 |
2024-08-08 |
Tune Therapeutics, Inc. |
Fusion proteins and systems for targeted activation of frataxin (fxn) and related methods
|
|
TW202509211A
(zh)
|
2023-04-26 |
2025-03-01 |
法商賽諾菲公司 |
宿主細胞系以及鑑定和使用該等宿主細胞系之方法
|
|
WO2025128817A1
(en)
|
2023-12-15 |
2025-06-19 |
Genzyme Corporation |
Artificial micrornas targeting tau
|
|
TW202548014A
(zh)
|
2024-01-26 |
2025-12-16 |
美商健臻公司 |
靶向亨丁頓舞蹈症之人工ｍｉｃｒｏｒｎａ
|
|
WO2025160429A1
(en)
|
2024-01-26 |
2025-07-31 |
Genzyme Corporation |
Artificial micrornas targeting snca
|
|
US20250276095A1
(en)
|
2024-03-04 |
2025-09-04 |
Kate Therapeutics, Inc. |
Adeno-associated virus compositions for the treatment of duchenne muscular dystrophy
|
|
WO2025226842A1
(en)
|
2024-04-24 |
2025-10-30 |
Kate Therapeutics, Inc. |
Expression control by drg-expressed mirnas
|
|
WO2025226841A1
(en)
|
2024-04-24 |
2025-10-30 |
Kate Therapeutics, Inc. |
Gene therapy approach for treating disorders associated with tnnt2
|
|
WO2026011008A1
(en)
|
2024-07-02 |
2026-01-08 |
Kate Therapeutics, Inc. |
Expression control by skeletal muscle-expressed mirnas
|
|
WO2026011009A1
(en)
|
2024-07-02 |
2026-01-08 |
Kate Therapeutics, Inc. |
Compositions and methods for muscle disorders
|
|
WO2026030242A1
(en)
|
2024-07-29 |
2026-02-05 |
Kate Therapeutics, Inc. |
Adeno-associated virus compositions for the treatment of facioscapulohumeral muscular dystrophy
|
|
WO2026030244A1
(en)
|
2024-07-30 |
2026-02-05 |
Kate Therapeutics, Inc. |
Adeno-associated virus compositions for the treatment of limb girdle muscular dystrophy 2a
|
|
WO2026050402A1
(en)
|
2024-08-29 |
2026-03-05 |
Kate Therapeutics, Inc. |
Liver de-targeted muscle tropic capsids
|